Stockreport

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis [Yahoo! Finance]

89bio, Inc.  (ETNB) 
Last 89bio, inc. earnings: 3/18 04:05 pm Check Earnings Report
PDF —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval with clinical outcomes to support the potential for confirma [Read more]